DongKoo Bio & Pharma Co. Ltd. (006620.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7006620009

Price
3,090.00 KRW
Market cap
83.56 bn KRW
P/E (2025)
1.66
P/S (2025)
0.34
Dividend yield
3.88 %
Net margin
20.71 %
Return on equity (ROE)
33.14 %
Return on assets (ROA)
14.95 %

DongKoo Bio & Pharma Co. Ltd. financials

Fiscal year20242025
Revenue249.27 bn KRW242.69 bn KRW
Gross profit152.03 bn KRW144.50 bn KRW
Operating income12.37 bn KRW9.25 bn KRW
EBIT6.71 bn KRW64.92 bn KRW
Net income2.04 bn KRW50.27 bn KRW
Diluted EPS – continuing operations73.73 KRW1,859.04 KRW

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About DongKoo Bio & Pharma Co. Ltd.

DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral, antifungal, antihistamines, antifebrile and anti-inflammatory analgesic, respiratory system, digestant, antiplatelet, other analgesics and antipyretics, nootropics and neurotonics, nonsteroidal anti-inflammatory, and oral hypoglycemic medicines; and antiphlogisnc enzyme, ophthalmic, dermatology external, and decongestants and nasal preparations, as well as non-selective a, ß-blockers and H+ pump inhibitors. It also provides cosmetic products under the CELL BLOOM brand; and SmartX, a kit-type SVF separation medical device for use in cosmetic surgery/anti-aging clinics and medical/treatments. The company was founded in 1970 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.